dctd-nanopi (Agenda)

DAY 1: October 18, 2022

Join Meeting – Computer Check

Welcome and Introduction
Janet Eary, M.D., Associate Director, CANCER IMAGING PROGRAM (CIP), DCTD, NCI
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI

Plenary presentation
Molly S Shoichet, Ph.D., UNIVERSITY OF TORONTO

The tumor microenvironment in nanoparticle delivery and function
Zaver, Bhujwalla, Ph.D., JOHNS HOPKINS UNIVERSITY

Imaging of nanotherapeutic drug action
Presented by Miles Miller, Ph.D., MASSACHUSETTS GENERAL HOSPITAL
(PI Ralph Weissleder, M.D., Ph.D., MASSACHUSETTS GENERAL HOSPITAL)

Copper-depleting nanotheranostics for treating triple negative breast cancer
Jianghong Rao, Ph.D., STANFORD UNIVERSITY

In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
Konstantin Sokolov, Ph.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Fluorescent indocarbocyanine PEGylated lipid nanoparticles for understanding and
overcoming barriers to drug delivery in invasive glioblastoma
Dmitri Simberg, Ph.D., UNIVERSITY OF COLORADO DENVER

LUNCH BREAK

Panel:

1. Andre Nel, M.D., Ph.D., UNIVERSITY OF CALIFORNIA, LOS ANGELES
2. Aleks Radovic-Moreno, Ph.D., LONGWOOD FUND
3. Stephan Stern, Ph.D., DABT, NANOTECHNOLOGY CHARACTERIZATION LABORATORY

Ultrasmall particle-based solutions for inducing ferroptosis and improving antitumor immune responses in cancer
Michelle Bradbury, M.D., Ph.D., MEMORIAL SLOAN KETTERING CANCER CENTER

Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
Lily Yang, M.D., Ph.D., EMORY UNIVERSITY

Nanodelivery platform for antibody drugs targeting NHL
Masakazu Kamata, Ph.D., UNIVERSITY OF ALABAMA AT BIRMINGHAM

Towards translation of MU-CN29: New therapeutic nanoparticle for drug resistant NSCLC
Raghuramann Kannan, M.D., UNIVERSITY OF MISSOURI-COLUMBIA

BREAK

Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
Gabriel Lopez-Berestein, M.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

TNBC ligand-displaying exosomes using RNA nanotechnology for targeted cytosol delivery of RNAi without endosome entrapment
Presented by Daniel Binzel, Ph.D., OHIO STATE UNIVERSITY (MPI)
(PI Dan Shu, M.D., OHIO STATE UNIVERSITY)

Novel approach to attenuate small cell lung cancer growth and metastasis
Mohd Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER

Q&A/Day 1 Wrap-up
Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI

DAY 2: October 19, 2022

Join Meeting-Computer Check

Day 1 recap

Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
Jin Xie, Ph.D., UNIVERSITY OF GEORGIA

The development of novel radiation-sensitizer based on ultra-small carbon dots
Zibo Li , Ph.D., UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL

Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial
chemotherapy of pancreatic ductal adenocarcinoma
Juan Luis Vivero-Escoto, Ph.D., UNIVERSITY OF NORTH CAROLINA, CHARLOTTE

Nanotechnology for targeted therapy and fundamental understanding of
therapeutic resistance in triple negative breast cancer
Xiaoming He, Ph.D., UNIVERSITY OF MARYLAND, COLLEGE PARK

Map leukemia-immune cell talks with nanoplasmon ruler in CAR T-cell immunotherapy
Presented by Pengyu Chen, Ph.D., AUBURN UNIVERSITY (MPI)
(PI Weiqiang Chen, Ph.D., NEW YORK UNIVERSITY)

LUNCH BREAK

PANEL:

1. Hannah Linden, M.D., F.A.C.P, FRED HUTCHINSON CANCER RESEARCH CENTER
2. Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER
3. Baran Sumer, M.D., F.A.C.S., UT SOUTHWESTERN MEDICAL CENTER

A cobalt porphyrin nanoliposome adjuvant for MHC-I-restricted cancer peptide vaccines
Jonathan Lovell, Ph.D., STATE UNIVERSITY OF NEW YORK AT BUFFALO

Innovative research for cancer nanotechnology (IRCN) for enhancing melanoma-
specific immune responses by the rational design of spherical nucleic acids
Presented by Bin Zhang, M.D., Ph.D., NORTHWESTERN UNIVERSITY (MPI)
(PI Chad Mirkin, Ph.D., NORTHWESTERN UNIVERSITY)

Targeting effector immune cells to cancer with chemically self-assembled nanorings (CSANs)
Carston Wagner, Ph.D., UNIVERSITY OF MINNESOTA

BREAK

Toward translation of an immunotherapeutic nanomedicine for neuroblastoma
John Tanner Wilson, Ph.D., VANDERBILT UNIVERSITY

Whitlockite nanoparticle-based immunotherapy for bone metastasis
Presented by Hae Lin Jang, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL (MPI)
(PI Shiladitya Sengupta, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL)

Toward translation of a plant virus-based in situ vaccination nanotechnology
Nicole Franziska Steinmetz, Ph.D., UNIVERSITY OF CALIFORNIA, SAN DIEGO

Closing Remarks
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI